Commentary on Young et al .: Clinical guidance is required for stimulant co‐prescription with opioid agonist therapy

Documenti analoghi

• Substance Use and Sex Index version 2 (SUSI‐2): Validation of a brief questionnaire for the measurement of behaviours associated with transmission of blood borne viruses and sexually transmitted infections
  di: Brendan Clifford, et al.
  Pubblicazione: (2025)
• Comment on Domzaridou et al .: Recognising the complexities of co‐prescriptions and lifestyle factors in opioid agonist treatment
  di: Adam Bakker, et al.
  Pubblicazione: (2024)
• Emergency department presentations, hospitalisations and police seizure data related to gamma‐hydroxybutyrate (GHB) in New South Wales, Australia, from 2015 to 2024
  di: Krista J. Siefried, et al.
  Pubblicazione: (2025)
• Recognizing the complexities of co‐prescriptions and life‐style factors in opioid agonist treatment: A response from Eleni Domzaridou, Matthew J. Carr, Tim Millar, Roger T. Webb and Darren M. Ashcroft
  di: Eleni Domzaridou, et al.
  Pubblicazione: (2024)
• Association between prescribed stimulant medications and overdose among individuals receiving opioid agonist therapy: A retrospective cohort study from British Columbia, Canada
  di: Samantha Young, et al.
  Pubblicazione: (2025)